In our weekly Trends that Matter series, we provide engaging infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is the state of pharma and biotech dealmaking.
Dealmaking in the pharmaceutical industry remains strong. Specifically, "Biopharma dealmaking in 2017 is robust and generally immune to external pressures in the short term," according to InVentiv Health Consulting’s Neel Patel.
Why is the industry so resilient? D. Crean of Objective Capital Partners elaborates:
“One possible reason for the resilience is that M&A in healthcare, pharma, biotech is often countercyclical. Larger bio-pharma companies are always going to be seeking new ways to expand inorganically and to consolidate to remain competitive and grow their top-line and earnings.”
To learn more about the dealmaking environment, check out this graphic created by InVentiv Health Consulting.